Neurofibromatosis 1 is an autosomal dominant, multisystem disorder with myriad clinical manifestations. Between 1991 and 1998, 495 adults and children were diagnosed with neurofibromatosis 1 at a specialized neurogenetics clinic in Sydney, Australia. This review establishes the prevalence of the clinical manifestations of neurofibromatosis 1 in these patients and provides guidelines for assessment and management. In addition, we review in detail patients who had unusual presentations and who represent important "exceptions to the rules" of clinical practice. (J Child Neurol 2002;17:613-621).
Get full access to this article
View all access options for this article.
References
1.
Huson SM, Harper PS, Compston DA: Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain1988;111:1355-1381.
2.
North KN: Clinical aspects of neurofibromatosis 1. Eur J Paediatr Neurol1998;2:223-231.
3.
Friedman JM, Birch P., Greene C.: National Neurofibromatosis Foundation International Database. Am J Med Genet1993;45: 88-91.
4.
Friedman JM, Birch PH: Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1728 patients . Am J Med Genet1997; 70:138-143.
5.
Riccardi VM: Neurofibromatosis: Phenotype, Natural History and Pathogenesis. Baltimore, Johns Hopkins University Press, 1992.
6.
Barker D., Wright E., Nguyen K., et al: Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science1987;236:1100-1102.
7.
Wallace MR, Marchuk DA, Andersen LB, et al: Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three neurofibromatosis 1 patients. Science1990;249:181-186.
8.
National Institutes of Health Consensus Development Conference.Neurofibromatosis. Conference statement. Arch Neurol1988;45:575-578.
9.
DeBella K., Szudek J., Friedman JM: Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics2000;105:608-614.
10.
Korf BR: Diagnostic outcome in children with multiple café au lait spots. Pediatrics1992;90:924-927.
11.
Waggoner D. , Towbin J., Gotesman G., Gutman DH: Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet2000 ;92:132-135.
12.
Zoller ME, Rembeck B., Oden A., et al: Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer1997;79:2125-2131.
13.
Lubs ML, Bauer MS, Formas ME, Djokic B.: Lisch nodules in neurofibromatosis type 1. N Engl J Med1991;324:1264-1266.
14.
Otsuka F., Kawashima, Imakado S, et al: Lisch nodules and skin manifestation in neurofibromatosis type 1. Arch Dermatol2001; 137:232-233.
15.
Listernick R., Lous D., Packer RJ, Gutmann DH: Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol1997;41:143-149.
16.
Mukonoweshuro W., Griffiths PD, Blaser S.: Neurofibromatosis type 1: The role of neuroradiology . Neuropediatrics1999;30: 111-119.
17.
Pollack I., Mulvihill JJ: Special issues in the management of gliomas in children with neurofibromatosis 1. J Neurooncol1996;28:257-268.
18.
Grill J., Couanet D., Cappelli C., et al: Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol1999;45:393-396.
19.
Hoffman HJ, Himphreys RP, Drake JM, et al: Optic pathway/hypothalamic gliomas, a dilemma in management . Pediatr Neurosurg1993;19:186-195.
20.
Perilongo G. , Moras P., Carollo C., et al: Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: A real possibility . J Child Neurol1999;14:352-356.
21.
Erkal HS, Serin M., Cakmak A.: Management of optic pathway and chiasmatic-hypothalamic gliomas in children with radiation therapy. Radiother Oncol1997 ;45:11-15.
22.
Habibi R., Silvermen B., Listernick R., Charrow J.: Precocious puberty in children with neurofibromatosis type 1. J Pediatr1995; 126:63-66.
23.
Cnossen MD, Stam E., Cooiman L., et al: Endocrinological disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics1997;100:667-670.
24.
Carmi D., Shohat M., Metzker A., Dickerman Z.: Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: A longitudinal study. Pediatrics1999; 103:1257-1262.
25.
Crawford AH , Baganey N.: Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop1986;6:77-88.
26.
Kim HW, Weinstein SL: Spine update. The management of scoliosis in neurofibromatosis. Spine1997;22:2770-2776.
27.
North K., Joy P., Yuille D., et al: Learning difficulties in neurofibromatosis type 1: The significance of MRI abnormalities. Neurology1994;44:878-883.
28.
Denckla MB, Hofman K., Mazzocco MM, et al: Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am JMed Genet1996;67:98-102.
29.
North KN, Riccardi VM, Samango-Sprouse C., et al: Cognitive function and academic performance in neurofibromatosis type 1: Statement from NF1 Cognitive Disorders Task Force. Neurology1997;48:1121-1127.
30.
Gutmann DH, Aylsworth A., Carey JC, et al: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis type 2. JAMA1997;278:51-57.
31.
Poyhonen M. , Niemela S., Herva R.: Risk of malignancy and death in neurofibromatosis . Arch Pathol Lab Med1997;121:139-143.
32.
Hamilton SJ , Allard MF, Friedman JM: Cardiac findings in an individual with neurofibromatosis 1 and sudden death. Am J Med Genet2001;100:95-99.
